<DOC>
	<DOCNO>NCT00501592</DOCNO>
	<brief_summary>The primary objective study ass , patient Type 2 diabetes mellitus ( DM ) presume nonalcoholic fatty liver disease ( NAFLD ) , follow : - The safety tolerability multiple dos INT 747 ; - The effect 2 dose level ( 25 mg 50 mg ) INT 747 insulin resistance glucose homeostasis ; - Effects INT-747 hepatocellular function measure assessment liver enzymes biochemical marker hepatic metabolic function inflammation , ; - Trough concentration INT-747 metabolite , glyco 6-ethyl chenodeoxycholic acid ( 6-EDCA ) tauro 6-ECDCA .</brief_summary>
	<brief_title>Study INT-747 Patients With Diabetes Presumed NAFLD</brief_title>
	<detailed_description>This multi-center , double-blind , randomize , placebo-controlled , multiple-dose , parallel-group study . Three ( 3 ) cohort 12 patient receive either placebo , 25 mg INT-747 , 50 mg INT-747 mouth daily 6 week . The primary objective assessing change insulin resistance glucose homeostasis attain perform euglycemic clamp procedure baseline ( Day 0 ) end 6 week treatment ( Day 43 ) . Other endpoint evaluate monitoring adverse experience ; vital sign ; clinical laboratory value ; plasma drug metabolite concentration ; general health well-being .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>Type 2 diabetes , define American Diabetes Association ( ADA ) , one follow criterion : Symptoms diabetes plus casual plasma glucose concentration &gt; 200 mg/dL ( 11.1 mmol/L ) Fasting plasma glucose &gt; 126 mg/dL ( 7.0 mmol/L ) 2hour postload glucose &gt; 200 mg/dL ( 11.1 mmol/L ) 75 g oral glucose tolerance test ( GTT ) . Presumed NAFLD , define one follow criterion : Alanine aminotransferase ( ALT ) ≥47 U/L female ≥56 U/L male Aspartate aminotransferase ( AST ) ≥47 U/L female ≥60 U/L male Enlarged liver ( demonstrate ultrasound image technique ) Diagnostic histological finding show prior biopsy ( last 5 year ) . Bilirubin &gt; 2 × ULN ALT &gt; 155 U/L female &gt; 185 U/L male . AST &gt; 155 U/L female &gt; 200 U/L male . Patients take antidiabetic medication , exception metformin sulfonylurea . If HbA1c &lt; 11 % , patient may enrol withdrawn diabetic medication specify protocol , discretion Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Farnesoid X receptor agonist</keyword>
	<keyword>Metabolic Disorder</keyword>
	<keyword>Diabetes</keyword>
	<keyword>NAFLD</keyword>
</DOC>